Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
Accept Policy
Change cookie settings
EmailIphone Application    Posted: 2019-08-16
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Stem cell treatment a ‘breakthrough’ for equine lameness
“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage".
Arti-Cell Forte is the first stem cell-based medicine to receive marketing authorisation

The first stem cell-based medicine to receive marketing authorisation for the treatment of equine lameness has been launched by Boehringer Ingelheim.

Hailed as a ‘breakthrough medicine’ for degenerative joint disease in horses, Arti-Cell Forte is the first ‘ready-to-use’ stem cell-based product to be licensed in any veterinary species. It is also the only stem cell treatment to contain induced cells, marking a significant step in stem cell therapies and medicine as a whole.

“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage,” explained DR Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager.

“Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses. This makes Arti-Cell® Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease.”

The medicine is available to veterinary practitioners direct from Boehringer Ingelheim. It is stored at ultra-low temperatures to maintain its two-year shelf life, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately before injecting. 

Full training on storage and administration of the medicine is available from the Boehringer via face-to-face CPD at practice meetings or specific CPD events. For more information about these events, email vetenquiries@boehringer-ingelheim.com 

Become a member or log in to add this story to your CPD history

Pair of endangered Amur leopard cubs born at Colchester Zoo

News Story 1
 Keepers at Colchester Zoo are hailing the arrival of a pair of critically endangered Amur leopard cubs.

The cubs were born to first-time parents Esra and Crispin on the 9 September. This is the first time the Zoo has bred Amur leopard cubs on-site.

Amur leopards originate from the Russian Far East and north-east China. In the wild they are threatened by climate change, habitat loss, deforestation and the illegal wildlife trade.

The cubs are said to be “looking well” and are expected to emerge from their den in a few weeks.  

Click here for more...
News Shorts
RCVS names Professor John Innes as chair of Fellowship Board

Professor John Innes has been elected chair of the 2019 RCVS Fellowship Board, replacing Professor Nick Bacon who comes to the end of his three-year term.


Professor Innes will be responsible for making sure the Fellowship progresses towards fulfilling its strategic goals, determining its ongoing strategy and objectives, and reporting to the RCVS Advancement of the Professions Committee on developments within the Fellowship.